Click Therapeutics Raises $48.5 Million to Boost Digital Healthcare
New York City, Thursday, 3 April 2025.
Click Therapeutics secures $48.5M in funding to enhance digital therapeutics, defying industry challenges and highlighting its role in treating diverse conditions such as depression and diabetes.
Strategic Growth in Digital Therapeutics
Click Therapeutics has demonstrated remarkable resilience in the digital therapeutics sector, successfully securing $48.5 million in funding as confirmed by public documents on April 2, 2025 [1]. This achievement is particularly noteworthy as the company emerges as one of the few prominent players maintaining strong investment momentum amid market challenges [1]. The company’s comprehensive portfolio addresses various conditions, including major depressive disorder, schizophrenia, opioid use disorder, insomnia, episodic migraines, type 2 diabetes, and multiple sclerosis [1].
Innovation and Strategic Partnerships
The company’s growth trajectory has been marked by significant strategic initiatives. In a notable development, Click Therapeutics has just unveiled a new brand identity and launched Click SE™, an innovative platform that combines digital therapeutic technology with pharmacotherapy [3]. This launch coincides with the company receiving FDA clearance for its groundbreaking prescription digital therapeutic for major depressive disorder [3]. The company’s partnership portfolio includes collaborations with pharmaceutical giants, highlighted by a remarkable $500 million-plus agreement with Boehringer Ingelheim in 2020 for developing a digital therapeutic for schizophrenia [1].
Market Position and Future Outlook
Click Therapeutics’ sustained ability to attract investment stands in stark contrast to industry trends, where competitors have faced significant challenges. The company’s leading product, Clickotine, designed for smoking cessation, exemplifies their practical application of digital therapeutics [2]. According to CEO David Benshoof Klein, the company has ‘made significant strides in the development of digital therapeutics and software-enhanced drug therapies, producing robust clinical data that demonstrates improved patient outcomes’ [3]. The recent funding is expected to further strengthen their position in software-based prescription medical treatments [3].